Search
Now showing items 1-2 of 2
HIV-1 diversity and the implementation of integrase strand-transfer inhibitors as part of combination antiretroviral therapy
(SAMA, 2020)
: The integrase (IN) strand-transfer inhibitor (InSTI)
dolutegravir (DTG) is now recommended by the World Health
Organization as part of salvage and/or first-line combination
antiretroviral therapy (cART).[1] DTG has a ...
Molecular dynamic simulations to investigate the structural impact of known drug resistance mutations on HIV-1C integrase-dolutegravir binding
(Public Library of Science, 2020)
Resistance associated mutations (RAMs) threaten the long-term success of combination antiretroviral therapy (cART) outcomes for HIV-1 treatment. HIV-1 Integrase (IN) strand transfer inhibitors (INSTIs) have proven to be a ...